Skip to content

Financial Information

This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQKPTI
Beta0.20
Shares Outstanding75.5M
Average Volume (10 days)1.6M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($2.79)
Sales (TTM)$1.50
Book Value (MRQ)($1.10)
Cash Flow (TTM)($2.47)
Cash (MRQ)$3.14

Analyst Views

Current Mean RecommendationBuy
Strong Buy3
 
Buy1
 
Hold3
 
Underperform0
 
Sell1
 

Recent Insider Transactions

Jatin Shah
EVP, Chief Medical Officer
(665)
Dispose
Jul 12, 2021
Sohanya Roshan Cheng
SVP Sales & Commercial Ops
7,500
Acquire
Jun 30, 2021
Stephen Mitchener
SVP, Chief Business Officer
(528)
Sell
Jun 2, 2021
Jatin Shah
EVP, Chief Medical Officer
23,250
Buy
May 7, 2021
Garen G. Bohlin
Director
4,000
Buy
May 6, 2021

Recent SEC Filings

S-8
Aug 5, 2021
S-3ASR
Aug 5, 2021
Quarterly Financials
Aug 5, 2021
Company Events
Aug 5, 2021
Insider Buy/Sell
Jul 13, 2021
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.